» Articles » PMID: 25732784

Chronic Stress Experience and Burnout Syndrome Have Appreciable Influence on Health-related Quality of Life in Patients with Psoriasis

Overview
Date 2015 Mar 4
PMID 25732784
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Psoriasis has a negative impact on health-related quality of life (HRQoL) and may favour mental comorbidity.

Objective: To investigate the contribution of chronic stress and burnout experience to HRQoL and how mental health influences the efficacy of an inpatient rehabilitation measure in psoriasis patients.

Methods: Eighty-four psoriasis patients taking part in a 3-week inpatient rehabilitation measure participated in the study. Severity of psoriasis was assessed with the Psoriasis Area and Severity Index (PASI) and by patients' self-evaluation at the beginning and end of treatment. The following aspects of mental health were explored using validated questionnaires. Symptoms of chronic stress and burnout experience: Trier Inventory for the Assessment of Chronic Stress (TICS) and Shirom Melamed Burnout Measure (SMBM). Symptoms of depression: depression scale of the Patient Health Questionnaire in the German version (PHQ-D). HRQoL: Dermatology Life Quality Index (DLQI) and Short Form Health Survey-8 (SF-8).

Results: Linear regression analyses revealed that chronic stress, burnout experience and perceived symptom severity but not clinician-assessed severity of psoriasis had independent negative effects on HRQoL. Patients who achieved a PASI reduction of <75% at discharge from the rehabilitation measure had lower baseline QoL and showed more symptoms of depression, chronic stress and burnout than patients who achieved a PASI improvement of ≥75.

Conclusion: Chronic stress and burnout have appreciable influence on HRQoL and may adversely affect treatment success in psoriasis patients. Our data underscore the importance of a multidimensional approach in the management of psoriasis.

Citing Articles

A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index.

Vyas J, Johns J, Ali F, Ingram J, Salek S, Finlay A Acta Derm Venereol. 2024; 104:adv41120.

PMID: 39508500 PMC: 11559262. DOI: 10.2340/actadv.v104.41120.


The IMPACT of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany.

Kahn M, Papukchieva S, Jacyshyn-Owen E, Grimm S, Eberl M, Schneeweiss S Dermatol Ther (Heidelb). 2023; 13(11):2609-2620.

PMID: 37710077 PMC: 10613167. DOI: 10.1007/s13555-023-01023-w.


The Impact of COVID-19 Pandemic on Dermatological Conditions: A Novel, Comprehensive Review.

Pendlebury G, Oro P, Haynes W, Merideth D, Bartling S, Bongiorno M Dermatopathology (Basel). 2022; 9(3):212-243.

PMID: 35892480 PMC: 9326733. DOI: 10.3390/dermatopathology9030027.


A Multivariate Analysis of Depression Prevalence in Psoriasis Patients: A Cohort Study.

Fabrazzo M, Romano F, Arrigo M, Puca R, Fuschillo A, De Santis V Int J Environ Res Public Health. 2022; 19(4).

PMID: 35206248 PMC: 8871876. DOI: 10.3390/ijerph19042060.


Implications of self-esteem in the quality of life in patients with psoriasis.

Brihan I, Ianosi S, Boda D, Halmajan A, Zdrinca M, Fekete L Exp Ther Med. 2020; 20(6):202.

PMID: 33123231 PMC: 7588787. DOI: 10.3892/etm.2020.9332.